BioSpace News Archive

With the amount of information on the internet increasing by the minute, retrieving data from it is like trying to find a needle in a haystack.

Citius Pharmaceuticals, Inc. have been accepted for presentations at the prestigious 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, December 10-13, 2022.

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs announced that it has regained compliance with the Nasdaq listing requirements.

Bridge to Life, Ltd. (“Bridge to Life” or the “Company”), a leading global supplier of organ preservation solutions and organ perfusion technologies, announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial (NCT05045794).

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255 on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates.

Eikonoklastes Therapeutics, a preclinical biotech company developing a 1st-in-class, AAV9-based gene therapy for treatment of sporadic and familial amyotrophic lateral sclerosis (ALS), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the ET-101 program.

Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that the company will participate in the Jefferies London Healthcare Conference scheduled to take place November 15-17, 2022.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the publication of a paper, “Introducing Bromelain-Based Enzymatic Debridement” in the journal Podiatry Management.

CinCor Pharma, Inc. announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom.